You are here
Home > Dilution > Piperacillin  


The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.    PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Usual Diluents


Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate]

[0 to 2 grams] [50 ml] [30 min]
[Over 2 grams] [100 ml] [30 min]

Stability / Miscellaneous

EXP: 1 DAY (RT) / 7 DAYS (REF). Label: Refrigerate.

IM injection: Dissolve each gram with 2 ml. Maximum of 2 grams per injection site. (May use SW, BS-SW, NS, 0.5 to 1% lidocaine).

Mild infection: 3-4g ivpb q6-8h
Serious infection: 3-4g ivpb q4-6h (200-300mg/kg/day)
Maximum 24g/day.

PIPRACIL may be administered by the intramuscular route (see NOTE) or intravenously as a three- to five-minute intravenous injection or as a 20- to 30-minute infusion. The usual dosage of PIPRACIL for serious infections is 3 to 4 g given every four to six hours as a 20- to 30-minute infusion. For serious infections, the intravenous route should be used.

PIPRACIL should not be mixed with an aminoglycoside in a syringe or infusion bottle since this can result in inactivation of the aminoglycoside.

The maximum daily dose for adults is usually 24 g/day, although higher doses have been used.

Intramuscular injections (see NOTE) should be limited to 2 g per injection site. This route of administration has been used primarily in the treatment of patients with uncomplicated gonorrhea and urinary tract infections.


Type of Infection Usual Total Daily Dose
†One g of probenecid should be given orally one-half hour prior to injection.
Serious infections such as septicemia, nosocomial pneumonia, intra-abdominal infections, aerobic and anaerobic gynecologic infections, and skin and soft tissue infections 12 – 18 g/d I.V. (200 – 300 mg/kg/d) in divided doses every 4 to 6 h
Complicated urinary tract infections 8 – 16 g/d I.V. (125 – 200 mg/kg/d) in divided doses every 6 to 8 h
Uncomplicated urinary tract infections and most community-acquired pneumonia 6 – 8 g/d I.M. or I.V. (100– 125 mg/kg/d) in divided doses every 6 to 12 h
Uncomplicated gonorrhea infections 2 g I.M.† as a one-time dose

The average duration of PIPRACIL treatment is from seven to ten days, except in the treatment of gynecologic infections, which is from three to ten days; the duration should be guided by the patient's clinical and bacteriological progress. For most acute infections, treatment should be continued for at least 48 to 72 hours after the patient becomes asymptomatic. Antibiotic therapy for S. pyogenes infections should be maintained for at least ten days to reduce the risk of rheumatic fever.

When PIPRACIL is given concurrently with aminoglycosides, both drugs should be used in full therapeutic doses.

Renal Impairment

Urinary Tract
Urinary Tract
>40 No dosage adjustment necessary
20-40 No dosage adjustment necessary 9 g/day
3 g every 8 h
12 g/day
4 g every 8 h
<20 6 g/day
3 g every 12 h
6 g/day
3 g every 12 h
8 g/day
4 g every 12 h

For patients on hemodialysis, the maximum daily dose is 6 g/day (2 g every 8 hours). In addition, because hemodialysis removes 30% to 50% of piperacillin in 4 hours, a 1-g additional dose should be administered following each dialysis period.

For patients with renal failure and hepatic insufficiency, measurement of serum levels of piperacillin will provide additional guidance for adjusting dosage.

When possible, PIPRACIL should be administered as a 20- to 30-minute infusion just prior to anesthesia. Administration while the patient is awake will facilitate identification of possible adverse reactions during drug infusion.

INDICATION 1st Dose 2nd Dose 3rd Dose
2 g I.V. just prior to surgery 2 g during surgery 2 g every 6 h Post-Op for no more than 24 h
2 g I.V. just prior to surgery 2 g 6 h after 1st dose 2 g 12 h after 1st dose
2 g I.V. after cord is clamped 2 g 4 h after 1st dose 2 g 8 h after 1st dose
2 g I.V. just prior to surgery 2 g on return to recovery room 2 g after 6 h


¶Either Parabens or Benzyl Alcohol.
#For Intramuscular Use Only. Lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.
Conventional Vials:
Diluents for Reconstitution
Sterile Water for Injection
Bacteriostatic¶ Water for Injection
Sodium Chloride Injection
Bacteriostatic¶ Sodium Chloride Injection
Dextrose 5% in Water
Dextrose 5% and 0.9% Sodium Chloride
Lidocaine# HCl 0.5-1% (without epinephrine)


††When PIPRACIL®is further diluted with Lactated Ringer's Injection, the diluted solution must be administered within 2 hours.
Conventional Vials:
Intravenous Solutions Intravenous Admixtures
Dextrose 5% in Water
0.9% Sodium Chloride
Dextrose 5% and 0.9% Sodium Chloride
Lactated Ringer's Injection††
Dextran 6% in 0.9% Sodium Chloride
Normal Saline [+ KCl 40 mEq]
5% Dextrose in Water [+ KCl 40 mEq]
5% Dextrose/Normal Saline [+ KCl 40 mEq]
Ringer's Injection [+ KCl 40 mEq]
Lactated Ringer's Injection [+ KCl 40 mEq]††

Intravenous Administration
Reconstitution Directions for Conventional Vials: Reconstitute each gram of PIPRACIL with at least 5 mL of a suitable diluent (except Lidocaine HCl 0.5%-1% without epinephrine) listed above. Shake well until dissolved. Reconstituted solution may be diluted to the desired volume (eg, 50 or 100 mL) in the above listed intravenous solutions and admixtures.

Intermittent IV Infusion
Infuse diluted solution over period of about 30 minutes. During infusion, it is desirable to discontinue the primary intravenous solution.

Intravenous Injection (Bolus)
Reconstituted solution should be injected slowly over a 3-to 5-minute period to help avoid vein irritation.


Intramuscular Administration
(Conventional Vials Only)

Reconstitution Directions:
Reconstitute each gram of PIPRACIL with 2 mL of a suitable diluent listed above to achieve a concentration of 1 g per 2.5 mL. Shake well until dissolved.

When indicated by clinical and bacteriological findings, intramuscularadministration of 6 to 8 g daily of PIPRACIL, in divided doses, may be utilized for initiation of therapy. In addition, intramuscular administration of the drug may be considered for maintenance therapy after clinical and bacteriologic improvement has been obtained with intravenous piperacillin sodium treatment. Intramuscular administration should not exceed 2 g per injection at any one site.

The preferred site is the upper outer quadrant of the buttock (ie, gluteus maximus).

The deltoid area should be used only if well-developed, and then only with caution to avoid radial nerve injury. Intramuscular injections should not be made into the lower or mid-third of the upper arm.

Stability of PIPRACIL Following Reconstitution
PIPRACIL is stable in both glass and plastic containers when reconstituted with recommended diluents and when diluted with the intravenous solutions and intravenous admixtures indicated above.

Pharmacy vials should be used immediately after reconstitution. Discard any unused portion after 24 hours if stored at room temperature (20° to 25°C [68° to 77°F]), or after 48 hours if stored at refrigerated temperature (2° to 8°C [36° to 46°F]). Vials should not be frozen after reconstitution.

How Supplied
PIPRACIL® (piperacillin for injection) is available in vials containing freeze-dried piperacillin sodium powder equivalent to two, three, and four g of piperacillin. One g of piperacillin (as a monosodium salt) contains 1.85 mEq (42.5 mg) of sodium.

Product Numbers
2 gram/Vial-10 per box-NDC 0206-3879-16
3 gram/Vial-10 per box-NDC 0206-3882-55
4 gram/Vial-10 per box-NDC 0206-3880-25

Store at controlled room temperature 20°C-25°C(68°F-77°F).

Wyeth Pharmaceuticals Inc.
Philadelphia, PA 19101

Rev 03/07

Source: [package insert]